Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START Pilot
NCT05255003Phase 4Recruiting
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of enoxaparin, dalteparin and tinzaparin in cancer-associated thrombosis (CAT) (2 arms). Primary endpoint: Average number of patients recruited per month at 18 months. Started Aug 2022; status: recruiting.
02
Drugs
enoxaparindalteparintinzaparin
03
Conditions
cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on NCT05255003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255003.